Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, 1603 W Taylor St, Chicago, IL 60612.
Metropolitan Chicago Breast Cancer Task Force, Chicago, IL.
AJR Am J Roentgenol. 2021 Apr;216(4):894-902. doi: 10.2214/AJR.19.22429. Epub 2021 Feb 10.
One central question pertaining to mammography quality relates to discerning the optimal recall rate to maximize cancer detection while minimizing unnecessary downstream diagnostic imaging and breast biopsies. We examined the trade-offs for higher recall rates in terms of biopsy recommendations and cancer detection in a single large health care organization. We included 2D analog, 2D digital, and 3D digital (tomosynthesis) screening mammography examinations among women 40-79 years old performed between January 1, 2005, and December 31, 2017, with cancer follow-up through 2018. There were 36, 67, and 38 radiologists who read at least 1000 2D analog examinations, 2D digital examinations, and 3D tomosynthesis examinations, respectively, who were included in these analyses. Using logistic regression with marginal standardization, we estimated radiologist-specific mean recall (abnormal interpretations/1000 mammograms), biopsy recommendation, cancer detection (screening-detected in situ and invasive cancers/1000 mammograms), and minimally invasive cancer detection rates while adjusting for differences in patient characteristics. Among 1,060,655 screening mammograms, the mean recall rate was 10.7%, the cancer detection rate was 4.0/1000 mammograms, and the biopsy recommendation rate was 1.60%. Recall rates between 7% and 9% appeared to maximize cancer detection while minimizing unnecessary biopsies. The results of this investigation are in contrast to those of a recent study suggesting appropriateness of higher recall rates. The "sweet spot" for optimal cancer detection appears to be in the recall rate range of 7-9% for both 2D digital mammography and 3D tomosynthesis. Too many women are being called back for diagnostic imaging, and new benchmarks could be set to reduce this burden.
一个与乳房 X 光摄影质量相关的核心问题是,确定最佳的召回率,在最大限度地提高癌症检出率的同时,最大限度地减少不必要的下游诊断成像和乳房活检。我们在单一大型医疗机构中检查了更高召回率在活检建议和癌症检测方面的权衡。我们纳入了 2005 年 1 月 1 日至 2017 年 12 月 31 日期间 40-79 岁女性的 2D 模拟、2D 数字和 3D 数字(断层合成)筛查乳房 X 光摄影检查,并通过 2018 年对癌症进行随访。有 36、67 和 38 位放射科医生分别阅读了至少 1000 次 2D 模拟检查、2D 数字检查和 3D 断层合成检查,这些分析包括这些放射科医生。我们使用边缘标准化的逻辑回归估计了每位放射科医生的平均召回率(异常解释/1000 张乳房 X 光片)、活检建议、癌症检出率(筛查检出的原位癌和浸润癌/1000 张乳房 X 光片)和微创癌症检出率,同时调整了患者特征的差异。在 1060655 次筛查性乳房 X 光片中,平均召回率为 10.7%,癌症检出率为 4.0/1000 张乳房 X 光片,活检建议率为 1.60%。7%至 9%之间的召回率似乎可以在最大限度地提高癌症检出率的同时最大限度地减少不必要的活检。这项调查的结果与最近一项研究的结果形成对比,该研究表明更高的召回率是合适的。对于 2D 数字乳房 X 光摄影和 3D 断层合成,最佳癌症检出的“最佳点”似乎在 7-9%的召回率范围内。太多的女性被召回进行诊断成像,新的基准可以设定来减轻这种负担。